Caribou Biosciences’ President And CEO Rachel Haurwitz Named To Fortune’s 2016 "40 Under 40" List Of Most Influential Young People In Business
BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a developer of CRISPR-Cas technologies for genome engineering, announced today that Rachel Haurwitz, Ph.D., President and Chief Executive Officer, has been selected for Fortune magazine’s 2016 “40 Under 40” list, the publication’s annual ranking of the most influential young people in business.
“She thought she was going to be a biotech patent IP lawyer, but Haurwitz’s love of science propelled her in another direction: partnering with famed biochemistry researcher Jennifer Doudna to cofound Caribou, one of the leading startups pursuing commercial applications of the genome-editing tool Crispr.”
Dr. Haurwitz, No. 23 on this year’s list, is a co-founder of Caribou and has served as President and CEO since its inception. As part of Dr. Haurwitz’s profile, Fortune notes “She thought she was going to be a biotech patent IP lawyer, but Haurwitz’s love of science propelled her in another direction: partnering with famed biochemistry researcher Jennifer Doudna to cofound Caribou, one of the leading startups pursuing commercial applications of the genome-editing tool Crispr.”
Dr. Haurwitz is also a co-founder of Intellia Therapeutics, where she serves as a member of the board of directors. She is an inventor on several patents and patent applications covering multiple CRISPR-derived technologies, and she has co-authored scientific papers in high impact journals characterizing CRISPR-Cas systems. Rachel earned an A.B. in Biological Sciences from Harvard College, and received a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.
The new issue of Fortune hits newsstands today.
About Caribou Biosciences
Caribou is a developer of cellular engineering and analysis solutions based on CRISPR technologies. The Company was founded by pioneers of CRISPR-Cas biology based on research carried out in the Doudna Laboratory at the University of California, Berkeley. Caribou's tools and technologies provide transformative capabilities to therapeutic development, agricultural biotechnology, industrial biotechnology, and basic and applied biological research. For more information, visit www.cariboubio.com and follow the Company @CaribouBio. "Caribou Biosciences" and the Caribou logo are trademarks of Caribou Biosciences, Inc.
Feinstein Kean Healthcare
Greg Kelley, 404-836-2302